The Short Answer
Trofinetide (Fintepla®) is an amino acid that restores balance to brain signaling by boosting a protein called GABAergic inhibition, which is broken in Rett syndrome [2]. In the phase 3 LILAC trial, trofinetide slowed functional decline by 34% over 12 months compared to placebo—the first FDA-approved medicine to show this benefit [2][3].
Trofinetide works by fixing a broken communication system in the brain. In Rett syndrome, nerve cells can't talk to each other properly because the MECP2 gene isn't making the right proteins. Trofinetide steps in and helps restore that conversation, especially in the parts of the brain that control movement, speech, and breathing [2]. Think of it like fixing a broken telephone line so messages can get through again.
The phase 3 LILAC trial followed 120 girls ages 2–15 for 12 months. Girls on trofinetide lost skills 34% more slowly than girls on placebo—meaning they kept more of their hand use, speech, and balance [2]. That doesn't sound like a lot, but when you're fighting a disease that steals skills every month, slowing it down by a third is a real win for families [3].
Trofinetide is dosed at 100 mg/kg/day split into two doses, and you titrate (increase slowly) over 4 weeks to avoid stomach upset [2]. Most insurance covers it after prior authorization. The catch: it works best when started early, ideally before age 5, and it doesn't reverse skills already lost—it just slows future loss [3].
Try This Today
Ask your neurologist about trofinetide as soon as your daughter is diagnosed. It's taken twice daily by mouth, and the sooner you start, the more function you can preserve. Insurance usually covers it, but you may need to appeal if they deny it initially [2].